# GHK-Cu Copper Peptide: Research Overview > GHK-Cu copper peptide: chemical identity, 50-year research history, mechanism of action, and comparative context. The most studied copper tripeptide in the peer-reviewed literature. ## GHK Copper Peptide: Chemical Identity and Research Context GHK-Cu copper peptide is the tripeptide glycyl-L-histidyl-L-lysine (GHK) chelated to a copper(II) ion in a 1:1 molar ratio. Systematic name: glycyl-L-histidyl-L-lysine copper(II) complex. INCI: Copper Tripeptide-1. Molecular weight of the peptide moiety: 340.4 Da. Synonyms used in the published literature: GHK-Cu, GHK copper peptide, copper tripeptide-1, glycyl-L-histidyl-L-lysine-Cu²⁺. Isolation: first identified from human plasma albumin in 1973 by Loren Pickart. The original observation was that the tripeptide stimulated hepatocyte survival and function; subsequent work revealed its endogenous presence in human plasma at physiological concentrations and its broad tissue-repair signaling properties.[18] The GHK-Cu literature now spans more than 50 years and approximately 20 primary mechanistic and efficacy studies catalogued on this site. Endogenous occurrence: GHK-Cu is found naturally in human plasma (approximately 200 ng/mL at age 20, declining to ~80 ng/mL by age 60), saliva, and urine.[18] It is also released from the extracellular matrix — specifically from the alpha2(I) chain of type I collagen — during tissue remodeling and injury, providing a locally timed repair signal.[1] ## Why Copper Matters: The Chelation Biology The copper(II) ion is not incidental — it is mechanistically required for most of GHK-Cu's documented biological effects. Copper complexation: - Renders the copper ion non-toxic and biologically available at nanomolar concentrations [1, 4] - Increases the partition coefficient of the GHK tripeptide, enhancing membrane permeability [4] - Delivers copper to intracellular copper-dependent enzymes including superoxide dismutase (SOD), lysyl oxidase, and cytochrome c oxidase [8] - Is required for VEGF-mediated angiogenesis activation — copper is an essential cofactor in the angiogenic pathway [5] Stripping the copper from the chelate changes the compound's biology. The free GHK tripeptide shows reduced — not zero — activity in some assays, but most of the well-documented mechanistic effects require the intact GHK-Cu complex.[17] The 2024 He et al. anti-fibrotic study used GHK (without copper) and documented integrin beta-1 signaling activation with anti-fibrotic effects in aged mouse myofibroblasts, identifying a copper-independent pathway for at least one GHK mechanism.[17] ## Fifty Years of GHK-Cu Research: Key Milestones 1973: GHK isolated from human plasma albumin by Pickart; initial observations on hepatocyte function. 1988: Maquart et al. publish fibroblast collagen stimulation at picomolar to nanomolar concentrations — the foundational in vitro efficacy study.[1] 2006: First human RCT with GHK-Cu (post-laser resurfacing, n=13) — subjective satisfaction improved significantly.[15] 2012: Pickart et al. identify GHK-Cu as a modulator of approximately 4,000+ human genes, framing it as a systemic aging-reset signal.[8] 2015: Pickart, Vasquez-Soltero, and Margolina document multiple cellular pathways in skin regeneration; largest-to-date human topical study (71 women, 12 weeks, photodamaged skin).[4, 13] 2017: Liposomal GHK-Cu accelerates scald wound healing in mice; VEGF/FGF-2 angiogenic mechanism confirmed.[5] Pickart et al. in Brain Sciences document neuroprotective gene-expression pattern.[7] 2018: Comprehensive gene-array synthesis in IJMS: ~31.2% of human genes modulated at ≥50% change at nanomolar concentrations.[2] Becomes the most-cited GHK-Cu paper. 2022: First pulmonary emphysema model study — Nrf2/Keap1 pathway confirmed as antioxidant mechanism.[9] 2023: Cu-GHK nanofiber hyaluronic acid hydrogel demonstrates enhanced wound closure vs non-copper controls in vivo.[10] 2024: GHK (without copper) documented as anti-fibrotic via integrin beta-1 signaling in aged myofibroblasts — first ITGb1 identification.[17] BioImpacts systematic review on anti-wrinkle evidence identifies methodological gaps.[14] 2025: SIRT1/STAT3 gastrointestinal mechanism documented in colitis model.[16] GHK-AgNP wound composite achieves 96% closure vs 22% control.[20] Liposomal penetration analytical gap identified — standardized measurement methods do not yet exist.[19] ## GHK-Cu vs. Other Copper Peptide Formulations The term 'copper peptide' in cosmetic and research contexts can refer to several distinct compounds. GHK-Cu (Copper Tripeptide-1, INCI) is the most studied and the most structurally characterized. Related forms include: - Pal-GHK (palmitoyl tripeptide-1): GHK with a palmitoyl fatty-acid tail for improved skin penetration. The 2024 BioImpacts review covers both GHK-Cu and Pal-GHK as anti-wrinkle ingredients, identifying Pal-GHK as having improved stratum corneum penetration vs native GHK-Cu.[14] Head-to-head clinical comparisons between the two forms do not exist in published literature. - GHKK, GHK-G, and other variants: Less studied; limited published data. The copper ion matters: formulations that degrade the copper-peptide complex — via low-pH co-formulation, poor storage, or strong chelating agents — lose most of the biological activity documented in the fibroblast and animal literature.[19] ## References [1] Maquart FX, et al. FEBS Letters. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/ [2] Pickart L, Margolina A. IJMS. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/ [4] Pickart L, et al. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ [5] Wang X, et al. Wound Repair and Regeneration. 2017;25(2):270-278. https://pubmed.ncbi.nlm.nih.gov/28370978/ [7] Pickart L, et al. Brain Sciences. 2017;7(2):20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5332963/ [8] Pickart L, et al. Oxidative Medicine and Cellular Longevity. 2012;2012:324832. https://pmc.ncbi.nlm.nih.gov/articles/PMC3359723/ [9] Zhang Q, et al. Frontiers in Molecular Biosciences. 2022;9:925700. https://pmc.ncbi.nlm.nih.gov/articles/PMC9354777/ [10] Lee S, et al. Acta Biomaterialia. 2023;172:159-174. https://pubmed.ncbi.nlm.nih.gov/37832839/ [13] Pickart L, et al. BioMed Research International. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ [14] Mortazavi SM, et al. BioImpacts. 2024. https://pubmed.ncbi.nlm.nih.gov/39963574/ [15] Miller TR, et al. Archives of Facial Plastic Surgery. 2006;8(4):252-259. https://pubmed.ncbi.nlm.nih.gov/16847171/ [16] Mao S, et al. Frontiers in Pharmacology. 2025. https://pubmed.ncbi.nlm.nih.gov/40672369/ [17] He Q, Mazzola J, Ladiges W. Aging Pathobiology and Therapeutics. 2024;6(4):186-190. https://pmc.ncbi.nlm.nih.gov/articles/PMC12352503/ [18] Dou Y, et al. Aging Pathobiology and Therapeutics. 2020;2(1):58-61. https://pubmed.ncbi.nlm.nih.gov/35083444/ [19] Ogorek K, et al. Molecules. 2025;30(1):136. https://pmc.ncbi.nlm.nih.gov/articles/PMC11721469/ [20] Adnan SB, et al. International Journal of Medical Sciences. 2025;22(16):4175-4200. --- Compiled from the gene-modulation script of the published GHK-Cu record — copper-biology indexed, not prescribed.